Small Cap Feast

Small Cap Feast – 22 October 2019

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 876

Total number of AIM Companies trading: 792*
* As at 21 October 2019

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): 87*

Total number of NEX Growth Market Companies trading: 85*
* As at 21 October 2019

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): 165*

Total number of Standard List Companies trading: 143*
* As at 21 October 2019

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?

Main Market premium

African Export-Import Bank a supranational financial institution whose purpose is to facilitate, promote and expand intra- and extra- African trade, of its potential intention to publish a registration document, the Bank hereby confirms its intention to proceed with an Initial Public Offering. The GDRs are expected to be admitted to the standard listing segment of the Official List of the FCA and to trading on the Main Market of the LSE.

DNEG Limited intends to apply for admission of its Shares to the premium listing segment of the Official List of the FCA and to trading on the London Stock Exchange’s main market for listed securities. The Offer will be comprised of new Shares to be issued by the Company (to raise expected gross proceeds of £150m). Admission is expected to take place in November 2019.

Breakfast Buffet

Thor Mining* (THR) 0.27p £2.67m

The Directors of Thor Mining announce a placing and subscription by directors to fund planned activities to progress the Company’s tungsten and copper projects and provide working capital.

Highlights:

The Company has raised gross proceeds of £510,000 through the placing of 113,333,333 new ordinary shares of 0.01p each and the conditional placing of 141,666,667 new Ordinary Shares at a price of 0.2p each.

Chairman Mick Billing to invest £20,000, and Non-executive Director David Thomas to invest £5,000 in the placing, subject to shareholder approval;

Funds raised increase existing cash balances and enables the Company to  progress work primarily at its core Molyhil (100% Thor) and adjacent Bonya (40% Thor) tungsten and molybdenum projects in the Northern Territory in Australia, and the EnviroCopper Ltd. In-Situ Copper Recovery project in South Australia, in which Thor currently holds a 25% stake.

Haydale Graphene Ind (HAYD) 1.4p £4.21m

Haydale, the global advanced materials group, has launched a range of graphene-enhanced prepreg material for lightning-strike protection, utilising functionalised nanomaterials to improve the electrical conductivity.

The material has been developed in collaboration with Airbus UK, BAE Systems, GE Aviation and Element Materials Technology Warwick Ltd, within the NATEP-supported GraCELs 2 project where the first iterations of materials were developed and subjected to lighting strike tests. The consortium is now looking to manufacture a demonstrator component using the materials developed to establish composite manufacturing protocols as a showcase part for commercial purposes.

This prepreg material delivers a new generation of carbon fibre-reinforced composites having improved electrical conductivity. These materials can be used for structural components as well as for enclosures for the electronic avionics systems.

Fusion Antibodies (FAB) 67.5p £14.69m

Fusion Antibodies, specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides a business and unaudited trading update for the six months ended 30 September 2019, confirming continued revenue growth and the commercial roll out of new services.

Highlights

Increase in orders and revenues in H1 FY2020 over H2 FY2019

First commercial projects for customers of the new Rational Affinity Maturation Platform (“RAMPTM”) service

Continuing development of Mammalian Antibody Library for delivery in 2020

Continued improvement in revenues for H1 FY2020 of £1.7m (H1 FY2019: £0.7m; H2 FY2019: £1.5m)

Trading for the year ending 31 March 2020 to date has been in line with market expectations

Adept (ADT) 310p £73.48m

Adept notes recent guidance by the departments  for education on keeping children safe in education or KCSIE.

The AdEPT development team have been working on enhancements to WebScreen for the last twelve months based on user feedback & AdEPT’s own design thinking.

In the latest version, schools have;

more control – over their own filtering policies.

greater autonomy – moving away from Local Authority oversight to better reflect the changes in the education sector.

Enhanced functionality – that makes administrating filtering at Multi-academy trusts simpler and more effective.

Bespoke capability – with features to allow staff & students to gain a unique filtering policy as soon as they log into their computer

After a positive reaction to the changes at the education in technology show, BETT the decision was made to upgrade the entire WebScreen estate during Easter of 2019.

Shearwater Group (SWG) 231p £50m

Shearwater Group plc, the organisational resilience group, announces that its group companies, Brookcourt Solutions, SecurEnvoy and GeoLang have won five awards collectively at the 2019 Computing Security Awards.

The category wins include, Security Company of the Year, Security Provider of the Year, Security Cloud-Delivered Security Solution of the Year, and Reseller of the Year.  At the same time, Dr Debbie Garside, the Group’s Chief Innovation Scientist and CEO of GeoLang, was also recognised for her contribution to the cyber security industry.

Vianet Group (VNET) 128.5p £35m

Vianet Group, the international provider of actionable data and business insight through devices connected to its Internet of Things platform, today provides the following trading update

The Group is pleased to report that trading for the first half of the current financial year has been strong, with revenue and operating profit growth in line with market expectations. 

The Smart Machines division, including Vendman, has delivered a strong year on year increase in the number of connected devices deployed, underpinned by three recent contract wins announced in August 2019.  These three long-term contracts with leading vending operators for a combined 20,000 units will generate in the region of £10m of revenue for the Group over their three to five-year contract terms.

Omega Diagnostics (ODX) 11.5p £17.3m

Omega, the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following trading update for the six months to 30 September 2019, in advance of releasing its interim results on Monday 2 December 2019.

Turnover is expected to be £4.46m, representing a 5% increase over the prior period from continuing operations. There is expected to be a minimal currency effect between revenues for this half-year period compared to the prior period and EBITDA and adjusted profit before tax (before share-based payments and amortisation of intangible assets) is in line with management expectation at the half-year stage.

Kropz (KRPZ) 9p £25m

Kropz plc, an emerging African phosphate producer, advises that, further to the announcement on 12 September 2019 regarding a delay to the proposed hearing date, an appeal hearing against Elandsfontein’s valid integrated water use licence is to commence today, Tuesday 22 October 2019.

The Company would like to advise the market that, in order to allow the Tribunal the appropriate opportunity to fully review the matter, it will not be providing further comment on the official proceedings until the Water Tribunal has announced their decision. The timing of the decision is currently unknown.

Pending the Water Tribunal’s decision, there is no legal impediment to the continuation of the water use activities authorised in the integrated WUL.

Creo Medical (CREO) 172.5p £209m

Creo Medical Group, a medical device company focused on the emerging field of surgical endoscopy, announces the full commercial launch of its Speedboat device, the first in a range of gastrointestinal (‘GI’) devices to be cleared for use with the CROMA Advanced Energy platform which uniquely combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation.

Online Blockchain (OBC) 19.5p £1.69m

Online Blockchain today discloses advancement details for FreeFaucet.io, one of its cryptocurrency and blockchain products.

The UK’s leading listed blockchain company reports that a hub for cryptocurrency faucets – has moved up 112,000 places to 31,933 in Alexa’s global internet traffic rankings in only 90 days[1]. Alexa Rank is a definitive and respected measure of website popularity calculated by looking at traffic and visitor engagement.

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.